Belgium has recently announced an expansion of its hospital formulary to include a broader range of biosimilar medicines, aiming to improve patient access and reduce healthcare costs. The Federal Agency for Medicines and Health Products (FAMHP) confirmed that additional biosimilars for conditions such as rheumatoid arthritis, diabetes, and oncology will now be available in public hospitals.

Biosimilars are highly similar versions of existing biological medicines and are rigorously evaluated for safety and efficacy. Their increased availability is expected to enhance treatment options for patients while supporting the sustainability of the healthcare system.

This policy update aligns with the European Medicines Agency's ongoing efforts to encourage the adoption of biosimilars across member states. Healthcare professionals in Belgium are encouraged to familiarize themselves with the updated formulary and discuss these options with eligible patients.